From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Identification of subjects at the early stages of Alzheimer's disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%-17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is informative for dementia research, since individuals with MCI have an increased annual conversion rate of 5–17% to Alzheimer’s disease (Cheng et al., 2017), and approximately 60% over a 15-year period of persons with SCD will continue to develop Alzheimer’s disease (Reisberg et al., 2008).”
From Mindfulness Training for People With Dementia and Their Caregivers: Rationale, Current Research, and Future Directions (2018) · cites this paper as Cheng et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“In 2011, the NIA-AA convened workgroups to revise diagnostic criteria for AD and its preclinical stages.(6,20,21) The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research sett…”
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research settings to stratify the level of certainty of underlying Alzheimer’s pathology.(21) During”
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“Following the development of biochemical and neuroimaging biomarkers, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) recommended a staging schema for preclinical AD based on biomarker status.(6) Subjects without cognitive decline are classified”
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986 · cited 1×
“that affect complex occupational and social activities but do not yet meet the criteria for dementia.(7,8) In 1999, Petersen et al redefined MCI as a syndrome of cognitive decline beyond that expected for an individual’s age and education level, but that does not notably interfere with activities of daily living.”
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 12×
“In 2012, the Subjective Cognitive Decline Initiative (SCD-I) formed a working group to generate a common concept and terminology for SCD.(58) The term “subjective cognitive decline” was suggested and was defined as a self-experienced persistent decline in cognitive capacity in comparison with the subject’s previously…”
InfluentialAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694 · cited 1×
“Adapting the expanded MCI criteria, the prevalence of MCI increased to 8%–25% of the elderly population aged $60 years.(13,14) In a systematic review published in 2013, the annual conversion rate of MCI to AD ranged from 7.”
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“(NMDA) receptor antagonist memantine are the only two classes of medication that have modest positive effects on cognitive decline.(1,2) Based on the evidence from”
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · cited 1×
“22,23 Abnormal CSF biomarkers, including lower β amyloid 1–42 (A β 42 ), higher phosphorylated tau 181 (P-tau), and higher total tau (t-tau) were observed in MCI patients who later converted to AD 24,25 or other dementia 24 compared with non-convertors.”
Mitchell, A. J., Beaumont, H., Ferguson, D., Yadegarfar, M., & Stubbs, B. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12336 · Cited by 1,162 · cited 1×
“56 Subjects with subjective cognitive decline may be a reasonable target for therapeutic trials.”
Mild cognitive impairment in the elderly: Predictors of dementia
Flicker, C., Ferris, S. H., & Reisberg, B. (1991) · Neurology · doi:10.1212/wnl.41.7.1006 · Cited by 838 · cited 1×
“7,8 In 1999, Petersen et al redefined MCI as a syndrome of cognitive decline beyond that expected for an individual’s age and education level, but that does not notably interfere with activities of daily living.”
Petersen, R. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520400044042 · Cited by 780 · cited 1×
“22,23 Abnormal CSF biomarkers, including lower β amyloid 1–42 (A β 42 ), higher phosphorylated tau 181 (P-tau), and higher total tau (t-tau) were observed in MCI patients who later converted to AD 24,25 or other dementia 24 compared with non-convertors.”
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Initiative, F. T. A. D. N. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 727 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Jessen, F. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.30 · Cited by 674 · cited 1×
“risk of developing AD or any dementia for SCD subjects with worries, compared with those without worries.(54) Confirmation”
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
The measurement of everyday cognition (ECog): Scale development and psychometric properties.
Farias, S. T., Mungas, D., Reed, B. R., Cahn-Weiner, D., Jagust, W., Baynes, K., & DeCarli, C. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.531 · Cited by 627
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614 · cited 1×
“72,73 Visser et al failed to find a significant association between abnormal A β 42 /tau ratios and conversion to dementia, 74 but only one SCD subject developed dementia during the 2.5-year follow-up period for that study.”
InfluentialJack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · cited 1×
“78 Petersen et al analyzed MCI subjects from The Mayo Clinic Study of Aging cohort and found that 29% of MCI subjects exhibited neurodegeneration without amyloid deposition.”
Cooper, C., Sommerlad, A., Lyketsos, C. G., & Livingston, G. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070878 · Cited by 570 · cited 2×
“39 Meanwhile, several studies showed a higher conversion rate from MCI to AD or other types of dementia in subjects with diabetes 40–42 or other vascular risk factors.”
Mild cognitive impairment: Disparity of incidence and prevalence estimates
Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.002 · Cited by 569 · cited 1×
“Early population-based studies showed that amnestic MCI affects 5%–10% of the elderly population.(12) Adapting the expanded MCI criteria, the prevalence of MCI increased to 8%–25% of the elderly population aged $60 years.”
Outcome over seven years of healthy adults with and without subjective cognitive impairment
Reisberg, B., Shulman, M. B., Torossian, C., Leng, L., & Zhu, W. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.10.002 · Cited by 568
Mild cognitive impairment: Long-term course of four clinical subtypes
Busse, A., Hensel, A., Gühne, U., Angermeyer, M. C., & Riedel-Heller, S. G. (2006) · Neurology · doi:10.1212/01.wnl.0000249117.23318.e1 · Cited by 561 · cited 1×
“15 19 In 2011, the NIA-AA convened workgroups to revise diagnostic criteria for AD and its preclinical stages.”
Rabin, L. A., Initiative, T. A. D. N., Smart, C. M., Crane, P. K., Amariglio, R. E., Berman, L. M., Boada, M., Buckley, R. F., Chételat, G., Dubois, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150154 · Cited by 462 · cited 2×
“used in previous studies and found significant heterogeneity among studies.(81) Measurements differ in response options, duration of reference timeframe, cognitive items assessed, and item specificity.”
Assessment of Memory Complaint in Age-Associated Memory Impairment: The MAC-Q
Crook, T. H., Feher, E. P., & Larrabee, G. J. (1992) · International Psychogeriatrics · doi:10.1017/s1041610292000991 · Cited by 432 · cited 1×
“Many measures were used only in a single study, 82–84 while the Memory Complaint Questionnaire (MAC-Q) 85 and the Everyday Cognition Scale (ECog) 86 were the most commonly used assessments across different studies.”
Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000354370 · Cited by 426 · cited 1×
“5% for community samples.(15) Consistent with previous findings that identified memory decline as the initial symptom of AD, amnestic MCI was associated with a higher risk of progression to AD in several longitudinal studies.”
Mild cognitive impairment and its management in older people
Ataollahi Eshkoor, S., Mun, C. Y., Ng, C. K., & Hamid, T. A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s73922 · Cited by 421 · cited 1×
“50 To stop the disease process, disease-modifying therapy may need to be initiated even before the onset of MCI.”
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage
Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., et al. (2015) · Brain · doi:10.1093/brain/awv029 · Cited by 383 · cited 1×
“35–38 In addition to biomarkers for Alzheimer’s pathology and neurodegeneration, the association between modifiable vascular risk factors and cognitive deterioration in MCI has gained considerable interest in recent years.”
Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
Li, J., Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., & Zhou, H. D. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7a4 · Cited by 367 · cited 1×
“Meanwhile, several studies showed a higher conversion rate from MCI to AD or other types of dementia in subjects with diabetes or other vascular risk factors.(40,41) In addition, well-controlled diabetes,(43) hypertension,(41) and dyslipidemia(41) were associated with a decreased risk of conversion to dementia.”
Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335
Abdulrab, K., & Heun, R. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.02.004 · Cited by 295 · cited 1×
“Variable terminology has been used in previous studies to describe this pre-MCI stage, including subjective cognitive impairment, subjective memory decline, subjective memory impairment, and memory complaints.(57) To generate comparability across studies, a consensus on the terminology and research criteria is crucial.”
Prevalence and Predictors of “Subjective Cognitive Complaints” in the Sydney Memory and Ageing Study
Slavin, M. J., Brodaty, H., Kochan, N. A., Crawford, J. D., Trollor, J. N., Draper, B., & Sachdev, P. S. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181df49fb · Cited by 290 · cited 1×
“community and clinic-based epidemiology studies have demonstrated the association between cognitive complaint and depression, anxiety,(59,61,63) and personality traits.(59,62) Other comorbidities that may contribute to cognitive complaints include physical health,(62,63) sleep problems, and concurrent medication use.”
Comijs, H. C., Deeg, D. J. H., Dik, M. G., Twisk, J. W. R., & Jonker, C. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00453-0 · Cited by 288 · cited 2×
“Several community and clinic-based epidemiology studies have demonstrated the association between cognitive complaint and depression, 59–63 anxiety, 59,61,63 and personality traits.”
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment
Scheef, L., Spottke, A., Daerr, M., Joe, A., Striepens, N., Kölsch, H., Popp, J., Daamen, M., Gorris, D., Heneka, M. T., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1a8d · Cited by 277
Eskildsen, S. F., Coupé, P., García-Lorenzo, D., Fonov, V., Pruessner, J. C., & Collins, D. L. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.058 · Cited by 269 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 266
Mild cognitive impairment due to Alzheimer disease in the community
Petersen, R. C., Aisen, P., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Knopman, D. S., Mielke, M., Pankratz, V. S., Roberts, R., Rocca, W. A., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23931 · Cited by 265 · cited 1×
“Petersen et al analyzed MCI subjects from The Mayo Clinic Study of Aging cohort and found that 29% of MCI subjects exhibited neurodegeneration without amyloid deposition.(79) In addition, these MCI subjects with neurodegeneration-only biomarker profiles had an increased risk of progression to AD, similar to subjects w…”
Shaffer, J. L., Petrella, J. R., Sheldon, F. C., Choudhury, K. R., Calhoun, V. D., Coleman, R. E., Doraiswamy, P. M., & Initiative, F. T. A. D. N. (2013) · Radiology · doi:10.1148/radiol.12120010 · Cited by 255
Ng, T. P., Feng, L., Nyunt, M. S. Z., Feng, L., Gao, Q., Lim, M. L., Collinson, S. L., Chong, M. S., Lim, W. S., Lee, T. S., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4899 · Cited by 250 · cited 1×
“Meanwhile, several studies showed a higher conversion rate from MCI to AD or other types of dementia in subjects with diabetes or other vascular risk factors.(40,41) In addition, well-controlled diabetes,(43) hypertension,(41) and dyslipidemia(41) were associated with a decreased risk of conversion to dementia.”
Memory complaints and APOE-ε4 accelerate cognitive decline in cognitively normal elderly
Dik, M. G., Jonker, C., Comijs, H. C., Bouter, L. M., Twisk, J. W. R., van Kamp, G. J., & Deeg, D. J. H. (2001) · Neurology · doi:10.1212/wnl.57.12.2217 · Cited by 233
Sun, Y., Lee, H.-J., Yang, S.-C., Chen, T.-F., Lin, K.-N., Lin, C.-C., Wang, P.-N., Tang, L.-Y., & Chiu, M.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100303 · Cited by 232 · cited 1×
“Adapting the expanded MCI criteria, the prevalence of MCI increased to 8%–25% of the elderly population aged $60 years.(13,14) In a systematic review published in 2013, the annual conversion rate of MCI to AD ranged from 7.”
Self-citationDonepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 213
The Subjective Cognitive Decline Questionnaire (SCD-Q): A Validation Study
Rami, L., Mollica, M. A., García-Sanchez, C., Saldaña, J., Sanchez, B., Sala, I., Valls-Pedret, C., Castellví, M., Olives, J., & Molinuevo, J. L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132027 · Cited by 200 · cited 1×
“Many measures were used only in a single study, 82–84 while the Memory Complaint Questionnaire (MAC-Q) 85 and the Everyday Cognition Scale (ECog) 86 were the most commonly used assessments across different studies.”
van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197 · cited 8×
“75 Hong et al tested visual rating scores for hippocampal atrophy and white matter hyperintensities to predict conversion to MCI and AD, but failed to show a significant association.”
InfluentialDONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 195
Self-reported memory complaints: Implications from a longitudinal cohort with autopsies
Kryscio, R. J., Abner, E. L., Cooper, G. E., Fardo, D. W., Jicha, G. A., Nelson, P. T., Smith, C. D., Van Eldik, L. J., Wan, L., & Schmitt, F. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000856 · Cited by 190
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184 · cited 1×
“35–38 In addition to biomarkers for Alzheimer’s pathology and neurodegeneration, the association between modifiable vascular risk factors and cognitive deterioration in MCI has gained considerable interest in recent years.”
Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, N., Pantieri, G., & Mariani, E. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000089515 · Cited by 182
Buckley, R., Saling, M. M., Ames, D., Rowe, C. C., Lautenschlager, N. T., Macaulay, S. L., Martins, R. N., Masters, C. L., O'Meara, T., Savage, G., et al. (2013) · International Psychogeriatrics · doi:10.1017/s1041610213000665 · Cited by 173 · cited 1×
“Several community and clinic-based epidemiology studies have demonstrated the association between cognitive complaint and depression, 59–63 anxiety, 59,61,63 and personality traits.”
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration
Leung, K. K., Bartlett, J. W., Barnes, J., Manning, E. N., Ourselin, S., Fox, N. C., & Initiative, F. T. A. D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e318281ccd3 · Cited by 165
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Patterns of subjective memory impairment in the elderly: association with memory performance
JESSEN, F., WIESE, B., CVETANOVSKA, G., FUCHS, A., KADUSZKIEWICZ, H., KÖLSCH, H., LUCK, T., MÖSCH, E., PENTZEK, M., RIEDEL-HELLER, S. G., et al. (2007) · Psychological Medicine · doi:10.1017/s0033291707001122 · Cited by 159 · cited 1×
“Many measures were used only in a single study, 82–84 while the Memory Complaint Questionnaire (MAC-Q) 85 and the Everyday Cognition Scale (ECog) 86 were the most commonly used assessments across different studies.”
Stewart, R., Godin, O., Crivello, F., Maillard, P., Mazoyer, B., Tzourio, C., & Dufouil, C. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.078683 · Cited by 155
Misiak, B., Leszek, J., & Kiejna, A. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.08.003 · Cited by 149 · cited 7×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
InfluentialSubjective cognitive decline: self and informant comparisons
Caselli, R. J., Chen, K., Locke, D. E. C., Lee, W., Roontiva, A., Bandy, D., Fleisher, A. S., & Reiman, E. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.003 · Cited by 145 · cited 2×
“However, some studies showed that cognitive decline reported by an informant, 64,65 or a mutual report from both the informant and the subject, 66 may better predict conversion to MCI or AD, compared with self-report.”
Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L., Trojanowski, J. Q., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 135 · cited 7×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
InfluentialPetersen, R. C. (1995) · JAMA · doi:10.1001/jama.273.16.1274 · Cited by 134
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318288690c · Cited by 133
Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease
Herholz, K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.136 · Cited by 129 · cited 1×
“26–29 Among biomarkers for neuronal injury, atrophy of medial temporal structures 30–32 and hypo-metabolism in the temporo-parietal cortices 33,34 were shown to predict a more rapid cognitive decline for subjects with MCI.”
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
Landau, S. M., Horng, A., Fero, A., Jagust, W. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002576 · Cited by 127
Progression of mild cognitive impairment to dementia due to AD in clinical settings
Tifratene, K., Robert, P., Metelkina, A., Pradier, C., & Dartigues, J. F. (2015) · Neurology · doi:10.1212/wnl.0000000000001788 · Cited by 124
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Isaac, M. G. E. K. N., Clark, A. R., Rusted, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub3 · Cited by 120
Ma, F., Wu, T., Miao, R., Xiao, Y. Y., Zhang, W., & Huang, G. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141566 · Cited by 104 · cited 1×
“40,41 In addition, well-controlled diabetes, 43 hypertension, 41 and dyslipidemia 41 were associated with a decreased risk of conversion to dementia.”
Selnes, P., Aarsland, D., Bjørnerud, A., Gjerstad, L., Wallin, A., Hessen, E., Reinvang, I., Grambaite, R., Auning, E., Kjærvik, V. K., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121603 · Cited by 101
Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98 · cited 1×
“67”
Stogmann, E., Moser, D., Klug, S., Gleiss, A., Auff, E., Dal-Bianco, P., Pusswald, G., & Lehrner, J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150785 · Cited by 73 · cited 1×
“community and clinic-based epidemiology studies have demonstrated the association between cognitive complaint and depression, anxiety,(59,61,63) and personality traits.(59,62) Other comorbidities that may contribute to cognitive complaints include physical health,(62,63) sleep problems, and concurrent medication use.”
Cognitive Complaints, Depressive Symptoms, and Cognitive Impairment: Are They Related?
Hohman, T. J., Beason‐Held, L. L., & Resnick, S. M. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03589.x · Cited by 72
Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives
Sun, Y., Yang, F., Lin, C., & Han, Y. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12395 · Cited by 71
Choo, I. H., Ni, R., Schöll, M., Wall, A., Almkvist, O., & Nordberg, A. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121489 · Cited by 57
Slavin, M. J., Sachdev, P. S., Kochan, N. A., Woolf, C., Crawford, J. D., Giskes, K., Reppermund, S., Trollor, J. N., Draper, B., Delbaere, K., et al. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.09.001 · Cited by 57 · cited 1×
“However, some studies showed that cognitive decline reported by an informant, 64,65 or a mutual report from both the informant and the subject, 66 may better predict conversion to MCI or AD, compared with self-report.”
Grimmer, T., Wutz, C., Drzezga, A., Forster, S., Forstl, H., Ortner, M., Perneczky, R., & Kurz, A. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010011 · Cited by 42
Vogel, A., Salem, L. C., Andersen, B. B., & Waldemar, G. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000272 · Cited by 41 · cited 1×
“In addition, very few studies have addressed the consistency and compatibility of different questionnaires.(87) The SCD-I working group offered several recommendations for measurement selection.”
Sierra-Rio, A., Balasa, M., Olives, J., Antonell, A., Iranzo, A., Castellví, M., Bosch, B., Grau-Rivera, O., Fernandez-Villullas, G., Rami, L., et al. (2016) · Neurodegenerative Diseases · doi:10.1159/000439258 · Cited by 40
Cerebrospinal Fluid Biomarkers Mirror Rate of Cognitive Decline
Rolstad, S., Berg, A. I., Bjerke, M., Johansson, B., Zetterberg, H., & Wallin, A. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121960 · Cited by 38 · cited 1×
“While van Harten et al reported that low Aβ 42 was the strongest predictor of conversion to MCI or AD,(71) Hessen et al and Rolstad et al found that high t-tau rather than Aβ 42 was correlated with future decline in memory and executive functions.(72,73) Visser et al failed to find a significant association between ab…”
Hong, Y. J., Yoon, B., Shim, Y. S., Kim, S., Kim, H. J., Choi, S. H., Jeong, J. H., Yoon, S. J., Yang, D. W., & Lee, J. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000430807 · Cited by 35 · cited 1×
“Hong et al tested visual rating scores for hippocampal atrophy and white matter hyperintensities to predict conversion to MCI and AD, but failed to show a significant association.(70) In summary, current evidence suggests that low CSF Aβ 42 and high t-tau or p-tau may help predict cognitive decline in SCD subjects, wh…”
Hessen, E., Nordlund, A., Stålhammar, J., Eckerström, M., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., & Wallin, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150109 · Cited by 23 · cited 1×
“While van Harten et al reported that low Aβ 42 was the strongest predictor of conversion to MCI or AD,(71) Hessen et al and Rolstad et al found that high t-tau rather than Aβ 42 was correlated with future decline in memory and executive functions.(72,73) Visser et al failed to find a significant association between ab…”
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70288-6 · Cited by 22
Grimmer, T., Wutz, C., Drzezga, A. E., et al. (2013) · Current Alzheimer Research · doi:10.2174/156720513804871499 · Cited by 20
Gifford, K. A., Liu, D., Hohman, T. J., Meng, X., Han, X., Romano, R. R., Fritzsche, L. R., Abel, T. W., & Jefferson, A. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141831 · Cited by 17
Self-reported memory complaints: Implications from a longitudinal cohort with autopsies
Jenkins, A. E., Bayer, A. J., Tree, J. J., & Tales, A. (2015) · Neurology · doi:10.1212/wnl.0000000000001677 · Cited by 13
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Mild Cognitive Impairment in Clinical Practice: A Review Article
Jongsiriyanyong, S., & Limpawattana, P. (2018) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317518791401 · Cited by 457
Gómez‐Ramírez, J., Ávila‐Villanueva, M., & Fernández‐Blázquez, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77296-4 · Cited by 127
Chopra, N., Wang, R., Maloney, B., Nho, K., Beck, J. S., Pourshafie, N., Niculescu, A., Saykin, A. J., Rinaldi, C., Counts, S. E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0610-2 · Cited by 101
Franco, G. A., Interdonato, L., Cordaro, M., Cuzzocrea, S., & Paola, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087318 · Cited by 115
“SCD has been prospectively linked to underlying AD pathology, and it is thought to likely accelerate memory decline [61].”
BackgroundSubjective cognitive decline: preclinical manifestation of Alzheimer’s disease
Lin, Y., Shan, P., Jiang, W., Sheng, C., & Ma, L. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3620-y · Cited by 100
Metadata
- Authors
- Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J.
- Affiliations
- National Taiwan University Hospital (TW)
- National Taiwan University (TW)
- Corresponding author
- Chiu, Ming-Jang
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume 13
- Pages
- 491-498
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5317337
- OpenAlex
- W2588980103
- Cited by
- 150
- References
- 98
- Citations by year
- 2026: 4 · 2025: 28 · 2024: 18 · 2023: 16 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 19 · 2018: 14 · 2017: 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- mild cognitive impairment, subjective cognitive decline, Alzheimer's disease, early detection of dementia, conversion to dementia, Alzheimer's disease biomarkers, risk prediction, normal aging, neurodegenerative diseases, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.